Core Insights - Eli Lilly anticipates approval from the U.S. Food and Drug Administration for its experimental oral obesity drug, orforglipron, by March 2026 [1] Company Summary - The chief executive of Eli Lilly provided the timeline for the expected FDA approval of orforglipron, indicating the company's confidence in the drug's potential [1]